Production & Sales

EQT offers to buy Karo Pharma for $654m

Private equity firm EQT has proposed to acquire 100% of Karo Pharma, a Swedish pharma company, for around SEK5.97bn ($654m).

Mayne Pharma acquires rights for psoriasis corticosteroid halobetasol foam

Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for a sum of up to $32m, which includes contingent payments of up to $17m based on commercial milestones and other factors.

Cipher launches Brinavess antiarrhythmic drug in Canada

Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.

J&J to acquire Japanese firm Ci:z for $2.04bn

Johnson & Johnson (J&J) has agreed to acquire all outstanding shares of Japanese skincare firm, Ci:z Holdings, in a deal valued at around ¥230bn ($2.04bn).

Quotient Sciences opens early-phase formulation and manufacturing plant in US

Drug development services provider Quotient Sciences has opened a 45,000ft² manufacturing facility near Philadelphia, in Garnet Valley, Pennsylvania.

Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India

Dr. Reddy’s Laboratories has agreed to divest its its API manufacturing business unit located in Jeedimetla, Hyderabad, located in the Indian state of Telangana, to generics pharmaceutical firm Therapiva Private.

eTheRNA immunotherapies opens mRNA manufacturing facility in Belgium

Clinical-stage firm eTheRNA immunotherapies has opened a mRNA facility in Belgium for production of mRNA immunotherapies.

Alliance Pharma launches nausea drug Xonvea in UK

Alliance Pharma has launched Xonvea, a new prescription drug for the treatment of nausea and vomiting of pregnancy (NVP), in the UK.

Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee

Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.